762757

    539997

    KPL

    img img img img
    No Data Available

    Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

    Kwality Pharmaceuticals L Share Price Today

    KWALITY PHARMACEUTICALS L made its stock market debut on 20 April 2026 and is currently trading at ₹2743, up by ₹41.0 from the previous close. The stock touched an intraday high of ₹2787.40 and a low of ₹2628.00 during the latest trading session.

    Kwality Pharmaceuticals L performance

    Today’s low Today’s high
    ₹ 2628.00 ₹ 2787.40
    ₹ 2743.00
    52 week low 52 week high
    ₹ 1561.00 ₹ 2890.30
    ₹ 2743.00
    Open Price ₹ 2688.50
    Prev. Close ₹ 2702.00
    Volume (Shares) 16659.00
    Total traded value ₹ 456.95
    Upper Circuit ₹ 3242.40
    Lower Circuit ₹ 2161.60
    info

    Investment Returns

    Over 1 Month 14.43% Over 3 Months 62.51% Over 6 Months 0.00% Over 1 Year 0.00%
    demotext Smart Investing Starts here ! Trade Smart with Fast Execution & Zero Account Opening Fees Invest Now

    Kwality Pharmaceuticals L fundamentals


    • Market cap (Cr) 2,846.20
    • P/E Ratio (TTM) 41.59
    • Beta 0.40
    • Book Value / share 320.51
    • Return on equity 16.27%
    • EPS (TTM) 65.50
    • Dividend yield 0.00%
    • Net profit/quarter (Cr) 25.29
    info icon alternate text
    • Market cap (Cr) 2,868.20
    • P/E Ratio (TTM) 41.59
    • Beta 0.59
    • Book Value / share 320.51
    • Return on equity 16.27%
    • EPS (TTM) 65.50
    • Dividend yield 0.00%
    • Net profit/quarter (Cr) 25.29
    info icon alternate text

    Kwality Pharmaceuticals L Financials

    • Key Results
    • Key Ratios
    • Balance sheet
    • Cash Flow
    • Competition
    Open financial information
    Revenue
    Net income
    Particulars MAR 2026 (Values in Cr)
    Revenue 156.82
    Operating Expense 126.23
    Net Profit 25.29
    Net Profit Margin (%) 16.12
    Earnings Per Share (EPS) 24.37
    EBITDA 39.80
    Effective Tax Rate (%) 20.09
    Particulars DEC 2025 (Values in Cr)
    Revenue 123.44
    Operating Expense 100.79
    Net Profit 16.01
    Net Profit Margin (%) 12.96
    Earnings Per Share (EPS) 15.43
    EBITDA 29.65
    Effective Tax Rate (%) 28.41
    Particulars SEP 2025 (Values in Cr)
    Revenue 111.31
    Operating Expense 93.76
    Net Profit 14.12
    Net Profit Margin (%) 12.68
    Earnings Per Share (EPS) 13.60
    EBITDA 26.25
    Effective Tax Rate (%) 23.46
    Particulars JUN 2025 (Values in Cr)
    Revenue 111.48
    Operating Expense 94.81
    Net Profit 11.93
    Net Profit Margin (%) 10.70
    Earnings Per Share (EPS) 11.50
    EBITDA 24.55
    Effective Tax Rate (%) 29.98
    Particulars MAR 2025 (Values in Cr)
    Revenue 115.68
    Operating Expense 97.35
    Net Profit 14.50
    Net Profit Margin (%) 12.53
    Earnings Per Share (EPS) 13.97
    EBITDA 26.65
    Effective Tax Rate (%) 24.04
    Particulars MAR 2026 (Values in Cr)
    Revenue 503.06
    Operating Expense 415.60
    Net Profit 67.35
    Net Profit Margin (%) 13.38
    Earnings Per Share (EPS) 64.90
    EBITDA 120.25
    Effective Tax Rate (%) 24.75
    Particulars MAR 2025 (Values in Cr)
    Revenue 370.20
    Operating Expense 317.89
    Net Profit 39.89
    Net Profit Margin (%) 10.77
    Earnings Per Share (EPS) 38.44
    EBITDA 82.37
    Effective Tax Rate (%) 26.44
    Particulars MAR 2024 (Values in Cr)
    Revenue 307.17
    Operating Expense 270.44
    Net Profit 23.98
    Net Profit Margin (%) 7.80
    Earnings Per Share (EPS) 23.11
    EBITDA 61.37
    Effective Tax Rate (%) 23.76
    Particulars MAR 2023 (Values in Cr)
    Revenue 250.99
    Operating Expense 211.64
    Net Profit 19.47
    Net Profit Margin (%) 7.75
    Earnings Per Share (EPS) 18.45
    EBITDA 46.70
    Effective Tax Rate (%) 24.41
    Particulars MAR 2022 (Values in Cr)
    Revenue 456.13
    Operating Expense 297.97
    Net Profit 120.05
    Net Profit Margin (%) 26.31
    Earnings Per Share (EPS) 115.70
    EBITDA 175.22
    Effective Tax Rate (%) 25.74
    Particulars MAR 2025 (Values in Cr)
    Book Value / Share 253.70
    ROE % 16.36
    ROCE % 18.35
    Total Debt to Total Equity 0.43
    EBITDA Margin 22.23
    Particulars MAR 2024 (Values in Cr)
    Book Value / Share 215.31
    ROE % 13.66
    ROCE % 15.86
    Total Debt to Total Equity 0.45
    EBITDA Margin 22.19
    Particulars MAR 2023 (Values in Cr)
    Book Value / Share 192.48
    ROE % 16.57
    ROCE % 18.50
    Total Debt to Total Equity 0.38
    EBITDA Margin 25.34
    Particulars MAR 2022 (Values in Cr)
    Book Value / Share 173.81
    ROE % 99.66
    ROCE % 94.93
    Total Debt to Total Equity 0.40
    EBITDA Margin 38.40
    Particulars MAR 2021 (Values in Cr)
    Book Value / Share 58.16
    ROE % 28.21
    ROCE % 23.78
    Total Debt to Total Equity 0.72
    EBITDA Margin 11.62
    Particulars MAR 2025 (Values in Cr)
    Book Value / Share 255.44
    ROE % 16.27
    ROCE % 18.29
    Total Debt to Total Equity 0.43
    EBITDA Margin 22.25
    Particulars MAR 2024 (Values in Cr)
    Book Value / Share 216.98
    ROE % 13.74
    ROCE % 15.90
    Total Debt to Total Equity 0.44
    EBITDA Margin 22.29
    Particulars MAR 2023 (Values in Cr)
    Book Value / Share 193.93
    ROE % 16.56
    ROCE % 18.47
    Total Debt to Total Equity 0.38
    EBITDA Margin 25.41
    Particulars MAR 2022 (Values in Cr)
    Book Value / Share 175.17
    ROE % 98.62
    ROCE % 94.24
    Total Debt to Total Equity 0.39
    EBITDA Margin 38.42
    Particulars MAR 2021 (Values in Cr)
    Book Value / Share 59.47
    ROE % 28.55
    ROCE % 23.96
    Total Debt to Total Equity 0.71
    EBITDA Margin 11.80
    Particulars MAR 2025 (Values in Cr)
    Cash & Short Term Investments 14.75
    Total Assets 447.27
    Total Liabilities 447.27
    Total Equity 262.39
    Share Outstanding 1
    Price to Book Ratio 3.40
    Return on Assets (%) 8.90
    Return on Capital (%) 10.63
    Particulars MAR 2024 (Values in Cr)
    Cash & Short Term Investments 5.94
    Total Assets 394.20
    Total Liabilities 394.20
    Total Equity 222.58
    Share Outstanding 1
    Price to Book Ratio 1.89
    Return on Assets (%) 6.03
    Return on Capital (%) 7.42
    Particulars MAR 2023 (Values in Cr)
    Cash & Short Term Investments 7.36
    Total Assets 353.63
    Total Liabilities 353.63
    Total Equity 199.06
    Share Outstanding 1
    Price to Book Ratio 1.59
    Return on Assets (%) 5.47
    Return on Capital (%) 6.7
    Particulars MAR 2022 (Values in Cr)
    Cash & Short Term Investments 12.95
    Total Assets 340.59
    Total Liabilities 340.59
    Total Equity 179.78
    Share Outstanding 1
    Price to Book Ratio 3.31
    Return on Assets (%) 35.23
    Return on Capital (%) 51.32
    Particulars MAR 2021 (Values in Cr)
    Cash & Short Term Investments 5.80
    Total Assets 166.26
    Total Liabilities 166.26
    Total Equity 59.85
    Share Outstanding 1
    Price to Book Ratio 0.94
    Return on Assets (%) 9.10
    Return on Capital (%) 16.02
    Particulars MAR 2025 (Values in Cr)
    Cash & Short Term Investments 14.28
    Total Assets 450.72
    Total Liabilities 450.72
    Total Equity 265.84
    Share Outstanding 1
    Price to Book Ratio 3.40
    Return on Assets (%) 8.85
    Return on Capital (%) 10.54
    Particulars MAR 2024 (Values in Cr)
    Cash & Short Term Investments 5.03
    Total Assets 397.57
    Total Liabilities 397.57
    Total Equity 225.94
    Share Outstanding 1
    Price to Book Ratio 1.89
    Return on Assets (%) 6.03
    Return on Capital (%) 7.4
    Particulars MAR 2023 (Values in Cr)
    Cash & Short Term Investments 6.09
    Total Assets 356.58
    Total Liabilities 356.58
    Total Equity 202.02
    Share Outstanding 1
    Price to Book Ratio 1.59
    Return on Assets (%) 5.45
    Return on Capital (%) 6.66
    Particulars MAR 2022 (Values in Cr)
    Cash & Short Term Investments 10.87
    Total Assets 342.67
    Total Liabilities 342.67
    Total Equity 182.55
    Share Outstanding 1
    Price to Book Ratio 3.31
    Return on Assets (%) 35.03
    Return on Capital (%) 50.75
    Particulars MAR 2021 (Values in Cr)
    Cash & Short Term Investments 5.13
    Total Assets 168.78
    Total Liabilities 168.78
    Total Equity 62.50
    Share Outstanding 1
    Price to Book Ratio 0.94
    Return on Assets (%) 9.13
    Return on Capital (%) 15.85
    Particulars MAR 2025 (Values in Cr)
    Net Income 54.13
    Cash from Operations 68.50
    Cash from Investing -28.51
    Cash from Financing -14.44
    Net change in Cash 9.76
    Free Cash Flow 91.80
    Particulars MAR 2024 (Values in Cr)
    Net Income 31.09
    Cash from Operations 44.28
    Cash from Investing -26.39
    Cash from Financing -17.39
    Net change in Cash -0.81
    Free Cash Flow 74.12
    Particulars MAR 2023 (Values in Cr)
    Net Income 25.57
    Cash from Operations 47.53
    Cash from Investing -48.44
    Cash from Financing 0.99
    Net change in Cash -6.06
    Free Cash Flow 95.21
    Particulars MAR 2022 (Values in Cr)
    Net Income 161.56
    Cash from Operations 101.95
    Cash from Investing -62.92
    Cash from Financing 5.65
    Net change in Cash 3.32
    Free Cash Flow 157.10
    Particulars MAR 2021 (Values in Cr)
    Net Income 21.27
    Cash from Operations 33.08
    Cash from Investing -23.20
    Cash from Financing 0.76
    Net change in Cash 4.27
    Free Cash Flow 56.48
    Particulars MAR 2025 (Values in Cr)
    Net Income 54.22
    Cash from Operations 68.56
    Cash from Investing -28.13
    Cash from Financing -14.44
    Net change in Cash 10.20
    Free Cash Flow 91.47
    Particulars MAR 2024 (Values in Cr)
    Net Income 31.46
    Cash from Operations 44.64
    Cash from Investing -26.39
    Cash from Financing -17.39
    Net change in Cash -0.44
    Free Cash Flow 74.48
    Particulars MAR 2023 (Values in Cr)
    Net Income 25.76
    Cash from Operations 48.34
    Cash from Investing -48.44
    Cash from Financing 0.99
    Net change in Cash -5.25
    Free Cash Flow 96.01
    Particulars MAR 2022 (Values in Cr)
    Net Income 161.67
    Cash from Operations 100.59
    Cash from Investing -62.97
    Cash from Financing 5.65
    Net change in Cash 1.92
    Free Cash Flow 155.75
    Particulars MAR 2021 (Values in Cr)
    Net Income 21.79
    Cash from Operations 32.73
    Cash from Investing -23.19
    Cash from Financing 0.82
    Net change in Cash 3.98
    Free Cash Flow 56.13
    Company Name Price P/E P/B Market Cap 52 Week Low 52 Week High
    AMBALAL SARABHAI ENT L 30.96 12.85 1.49 237.26 23.12 38.85
    BLISS GVS PHARMA LTD 482.50 38.79 4.28 5117.21 118.35 552.90
    CIPLA LTD. 1418.40 30.10 3.32 114584.78 1165.55 1672.20
    FERMENTA BIOTECH LIMITED 431.50 19.03 3.12 1269.95 256.40 480.00
    Company Name Price P/E P/B Market Cap 52 Week Low 52 Week High
    AMBALAL SARABHAI ENT L 30.96 21.65 3.98 237.26 23.12 38.85
    AMRUTANJAN HEALTH CARE LTD. 537.90 24.11 4.20 1555.10 490.00 789.95
    ASTRAZENECA PHARMA IND LT 8025.95 104.82 22.98 20064.88 7630.00 9850.00
    BLISS GVS PHARMA LTD 482.50 52.16 4.42 5117.21 118.35 552.90

    Kwality Pharmaceuticals L shareholding pattern

    Holding
    41.98%
    54.86%
    2.78%
    0.35%
    Name Shares Category
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)

    Kwality Pharmaceuticals L Technicals Summary

    • EMA & SMA
    • Resistance and Support
    • Delivery and Volume
    • Beta
    • Price Change Analysis
    2743.00 1.51 redarrow
    red-green-graph indicator
    0 Bearish
    16 Bullish
    • 5 Days 2706.30
    • 26 Days 2549.30
    • 10 Days 2672.90
    • 50 Days 2304.60
    • 12 Days 2660.10
    • 100 Days 2194.60
    • 20 Days 2601.70
    • 200 Days 2194.60
    2750.37 PIVOT
    First Support 2640.83 First Resistance 2811.53 Second Support 2579.67 Second Resistance 2921.07 Third Support 2470.13 Third Resistance 2982.23
    RSI 58.62 ADX 40.73 MACD 110.75 Williams % R -49.71 Commodity Channel Index (CCI) 87.77
    Date 2026-07-17 Week 10474.00 Same Day 9962.00 Month 15166.00
    1 Year 0.40 3 Year 0.35
    Over 1 Month
    14.43% down
    Over 1 Year
    0.00% down
    Over 3 Months
    62.51% down
    Over 3 Years
    0.00% down
    Over 6 Months
    0.00% down
    Over 5 Years
    0.00% down

    Kwality Pharmaceuticals L Corporate Actions

    Dividend date Dividend amount Dividend type Record date Instrument type
    05 Jan 2017 0.6 Interim 06 Jan 2017 Equity shares
    Ex-Date Ex-Bonus Ratio
    12 Oct 2017 11 Oct 2017 1:1
    Dividend date Dividend amount Dividend type Record date Instrument type
    05 Jan 2017 0.6 Interim 06 Jan 2017 Equity shares
    Ex-Date Ex-Bonus Ratio
    12 Oct 2017 11 Oct 2017 1:1

    Top Gainers

    Top Losers

    stock
    Trade stocks with ease

    Sign-in to trade with your demat account, or set up a new demat account for free

    Board Of Directors

    Similar stocks

    Frequently Asked Questions

    What is the Current Share Price of Kwality Pharmaceuticals Ltd?

    Answer Field

    Kwality Pharmaceuticals Ltd share price is for NSE ₹ 2,743.00 & for BSE ₹ 2,756.40 as on Jul 20 2026 03:30 PM.

    What is the Market Cap of Kwality Pharmaceuticals Ltd Share?

    Answer Field

    The market cap of Kwality Pharmaceuticals Ltd for NSE ₹ 0.00 & for BSE ₹ 0.00 as on Jul 20 2026 03:30 PM.

    What is the 52 Week High and Low of Kwality Pharmaceuticals Ltd?

    Answer Field

    The 52 Week High and Low of Kwality Pharmaceuticals Ltd for NSE is ₹ 2,890.30 and ₹ 1,561.00 and for BSE is ₹ 2,889.00 and ₹ 828.80.

    What is 1 year return for Kwality Pharmaceuticals Ltd?

    Answer Field

    The 1 year returns on the stock has been 0.00%.

    What is the P/E Ratio of Kwality Pharmaceuticals Ltd Share?

    Answer Field

    As on Jul 20 2026 03:30 PM the price-to-earnings (PE) ratio for Kwality Pharmaceuticals Ltd share is 41.59.

    What is the PB ratio of Kwality Pharmaceuticals Ltd Share?

    Answer Field

    As on Jul 20 2026 03:30 PM, the price-to-book (PB) ratio for Kwality Pharmaceuticals Ltd share is 320.51.

    How to Buy Kwality Pharmaceuticals Ltd Share?

    Answer Field

    You can trade in Kwality Pharmaceuticals Ltd shares with Bajaj Broking by opening a demat account.

    How to Buy Kwality Pharmaceuticals Ltd Share on Bajaj Broking App?

    Answer Field

    To buy Kwality Pharmaceuticals Ltd shares on the Bajaj Broking app, follow these steps:

    • Login to the Bajaj Broking App

    • Click on the Search Icon

    • Search “Kwality Pharmaceuticals Ltd”

    • Click on the BUY icon

    • Place a buy order specifying the desired quantity of shares.

    • Click BUY again to complete the purchase

    No results found

    close-img
    Authorise with OTP
    Enter the 4-Digit OTP sent to
    edit
    OTP expires in 00:59
    banner-icon

    Open Your Free Demat Account

    Enjoy low brokerage on delivery trades

    +91

    |

    Open Your Free Demat Account

    Enjoy low brokerage on delivery trades

    +91

    |